Why Spero Therapeutics, Inc. (SPRO) Surged Last Week

We recently published a list of Small Stocks, But Explosive: These 10 Firms Crushed The Market Last Week. In this article, we are going to take a look at where Spero Therapeutics, Inc. (NASDAQ:SPRO) stands against other firms that led last week’s charge.

Spero Therapeutics soared by 259 percent week-on-week as investors cheered encouraging results of its potential treatment for urinary tract infection.

According to the company, its study for the oral drug tebipenem HBr, which it was developing in partnership with pharmaceutical giant GSK, showed that it was at least as good as an intravenous imipenem-cilastatin, a type of antibiotic, in hospitalized adult patients.

If approved, it could become the first oral carbapenem antibiotic for patients with cUTIs.

The news pushed the company to touch a new all-time high of $2.8 on Friday and propelled its price above the $1 level, having traded below the said price for 94 consecutive days.

A scientist in a lab coat holding a vial filled with a blue glowing liquid, representing the clinical-stage biopharmaceutical company’s research in rare diseases.

Earlier this year, Spero Therapeutics, Inc. (NASDAQ:SPRO) received a letter from the Nasdaq notifying the company of failing to meet the minimum bid price requirement of $1.

As a Nasdaq-listed company, it is required to stay afloat the minimum requirement to stay listed, or face a potential delisting. Spero Therapeutics, Inc. (NASDAQ:SPRO) had until August 25 to regain compliance.

Overall, SPRO ranks 4th on our list of firms that led last week’s charge. While we acknowledge the potential of SPRO, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than SPRO and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.

Disclosure: None. This article is originally published at Insider Monkey.